CN101547705B - 用于治疗新生物的组合物和方法 - Google Patents

用于治疗新生物的组合物和方法 Download PDF

Info

Publication number
CN101547705B
CN101547705B CN2007800451061A CN200780045106A CN101547705B CN 101547705 B CN101547705 B CN 101547705B CN 2007800451061 A CN2007800451061 A CN 2007800451061A CN 200780045106 A CN200780045106 A CN 200780045106A CN 101547705 B CN101547705 B CN 101547705B
Authority
CN
China
Prior art keywords
purposes
antibody
vegf
bortezomib
thalidomide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800451061A
Other languages
English (en)
Chinese (zh)
Other versions
CN101547705A (zh
Inventor
罗伯特·D·马斯
格雷戈里·D·普洛曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN101547705A publication Critical patent/CN101547705A/zh
Application granted granted Critical
Publication of CN101547705B publication Critical patent/CN101547705B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2007800451061A 2006-12-11 2007-05-04 用于治疗新生物的组合物和方法 Expired - Fee Related CN101547705B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87446006P 2006-12-11 2006-12-11
US60/874,460 2006-12-11
PCT/US2007/068300 WO2008073509A2 (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm

Publications (2)

Publication Number Publication Date
CN101547705A CN101547705A (zh) 2009-09-30
CN101547705B true CN101547705B (zh) 2013-06-12

Family

ID=38521756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800451061A Expired - Fee Related CN101547705B (zh) 2006-12-11 2007-05-04 用于治疗新生物的组合物和方法

Country Status (17)

Country Link
US (1) US20100086544A1 (enExample)
EP (1) EP2099489B1 (enExample)
JP (1) JP2010512407A (enExample)
KR (1) KR101320198B1 (enExample)
CN (1) CN101547705B (enExample)
AU (1) AU2007333565A1 (enExample)
BR (1) BRPI0717688A2 (enExample)
CA (1) CA2670707A1 (enExample)
DK (1) DK2099489T3 (enExample)
IL (1) IL198852A (enExample)
MX (1) MX2009006202A (enExample)
NZ (1) NZ577058A (enExample)
RU (1) RU2482877C2 (enExample)
SG (1) SG177891A1 (enExample)
SI (1) SI2099489T1 (enExample)
WO (1) WO2008073509A2 (enExample)
ZA (1) ZA200903489B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2066694T1 (sl) * 2006-09-29 2016-02-29 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za diagnosticiranje in zdravljenje raka
TR201818814T4 (tr) 2009-10-16 2019-01-21 Oncomed Pharm Inc Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
PT3485903T (pt) 2011-09-23 2023-02-17 Mereo Biopharma 5 Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
EP2825162B1 (en) * 2012-03-14 2018-09-12 Indiana University Research and Technology Corporation Compounds and methods for treating leukemia
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
GB201409471D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
MX376585B (es) 2015-07-27 2025-03-07 Chong Kun Dang Pharmaceutical Corp Compuestos derivados de sulfamida de 1,3,4-oxadiazol como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos.
AU2016299485B2 (en) 2015-07-27 2019-02-07 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
ES2935932T3 (es) 2015-07-27 2023-03-13 Chong Kun Dang Pharmaceutical Corp Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
AU2016303891B2 (en) 2015-08-04 2019-08-01 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
HUE061967T2 (hu) 2015-10-12 2023-09-28 Chong Kun Dang Pharmaceutical Corp Hiszton deacetiláz-6 inhibitor oxadiazol-amin származékok és az azokat tartalmazó gyógyászati készítmény
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
SG11202007130RA (en) 2018-01-26 2020-08-28 Univ California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
PH12021552905A1 (en) 2019-05-31 2022-04-04 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
PL346898A1 (en) * 1998-09-25 2002-03-11 Boehringer Ingelheim Pharma Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6638965B2 (en) * 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
TWI580694B (zh) * 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Phase II trial of SCIO-469 as monotherapy or in combination with bortezomib in replased refractory multiple myeloma;SIEGEL DAVID,ET AL;《BIOSCIENCES INFORMATION SERVICE》;20061130;摘要 *
RICHARDSON P G,ET AL.A multi-center,randomized,phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone for the treatment of relapsed or refactory multiple myeloma.《BIOSCIENCES INFORMATION SERVICE》.2003, *

Also Published As

Publication number Publication date
RU2009126588A (ru) 2011-01-20
SG177891A1 (en) 2012-02-28
MX2009006202A (es) 2009-06-22
AU2007333565A1 (en) 2008-06-19
JP2010512407A (ja) 2010-04-22
EP2099489A2 (en) 2009-09-16
SI2099489T1 (sl) 2014-09-30
WO2008073509A3 (en) 2009-01-08
ZA200903489B (en) 2010-08-25
WO2008073509A2 (en) 2008-06-19
CA2670707A1 (en) 2008-06-19
IL198852A (en) 2013-06-27
DK2099489T3 (da) 2014-08-18
CN101547705A (zh) 2009-09-30
IL198852A0 (en) 2011-08-01
NZ577058A (en) 2012-04-27
BRPI0717688A2 (pt) 2013-01-22
EP2099489B1 (en) 2014-05-21
KR101320198B1 (ko) 2013-10-30
US20100086544A1 (en) 2010-04-08
RU2482877C2 (ru) 2013-05-27
HK1131064A1 (en) 2010-01-15
KR20090087908A (ko) 2009-08-18

Similar Documents

Publication Publication Date Title
CN101547705B (zh) 用于治疗新生物的组合物和方法
JP6788600B2 (ja) がんを治療するための、ｐｄ−１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
CN112203695B (zh) 用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
US20230340122A1 (en) Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
CN113260385B (zh) 抗vegf抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法
JP7402691B2 (ja) 抗ｃｄ２５抗体薬物複合体による併用療法
CN119868579A (zh) 抗组织因子抗体-药物偶联物及其在癌症治疗中的应用
US20240368269A1 (en) Anti-dll3 antibodies and uses thereof
JP5220315B2 (ja) 抗ＥｐＣＡＭ免疫グロブリン
JP7590083B2 (ja) 併用療法
US20240218066A1 (en) Use of anti-pd-1 antibody in combination with first-line chemotherapy in treatment of advanced non-small cell lung cancer
CN112367999A (zh) 组合疗法
CA3213216A1 (en) Tgf-beta inhibitors and use thereof
WO2023172951A1 (en) Methods of treating solid tumors with anti-tissue factor antibody-drug conjugates
CA3199259A1 (en) Her3 radioimmunotherapy for the treatment of solid cancers
AU2016222436A1 (en) Compositions and methods for treating a neoplasm
AU2014201911A1 (en) Compositions and methods for treating a neoplasm
HK1131064B (en) Compositions and methods for treating a neoplasm
WO2024213081A1 (zh) 抗体药物偶联物在制备预防和/或治疗癌症的药物中的用途
BR122024026022A2 (pt) Uso de um anticorpo, ou fragmento funcional ou variante funcional do mesmo, e de uma proteína de fusão para o tratamento de câncer
HK40045175A (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
CN118613280A (zh) 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130612

Termination date: 20200504

CF01 Termination of patent right due to non-payment of annual fee